Literature DB >> 17353299

Declines in low birth weight and preterm birth among infants who were born to HIV-infected women during an era of increased use of maternal antiretroviral drugs: Pediatric Spectrum of HIV Disease, 1989-2004.

Joann Schulte1, Ken Dominguez, Thomas Sukalac, Beverly Bohannon, Mary Glenn Fowler.   

Abstract

OBJECTIVE: Our goal was to determine trends in low birth weight and preterm birth among US infants born to HIV-infected women.
METHODS: We used data from the longitudinal Pediatric Spectrum of HIV Disease, a large HIV cohort, to assess trends in low birth weight and preterm birth from 1989 to 2004 among 11,321 study infants. Among women with prenatal care, we also assessed risk factors, including maternal antiretroviral therapy during pregnancy, that were predictive of low birth weight and preterm birth using univariate and multivariate logistic regression models.
RESULTS: Overall, 11,231 of 14,464 infants who were enrolled in Pediatric Spectrum of HIV Disease were tested during the neonatal period. From 1989 to 2004, testing increased from 32% to 97%. The proportion of HIV-exposed infants who had low birth weight decreased from 35% to 21% and occurred in all racial/ethnic groups. Prevalence of preterm birth decreased from 35% to 22% and occurred in all groups. Any maternal antiretroviral therapy use increased from 2% to 84%. Among 8793 women who had prenatal care, low birth weight was associated with a history of illicit maternal drug use, unknown maternal HIV status before delivery, symptomatic maternal HIV disease, black race, Hispanic ethnicity, and infant HIV infection. Antiretroviral therapy or lack of it was not associated with low birth weight. Among women with prenatal care, preterm birth was associated with a history of illicit maternal drug use, symptomatic maternal HIV disease, no antiretroviral therapy, receipt of a 3-drug highly active antiretroviral therapy regimen with protease inhibitors, black race, and infant HIV infection.
CONCLUSIONS: The proportion of infants who had low birth weight or were born preterm declined during an era of increased maternal antiretroviral therapies. These Pediatric Spectrum of HIV Disease trends differ from the overall increases in both outcomes among the US population.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17353299     DOI: 10.1542/peds.2006-1123

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  51 in total

1.  Substance use in HIV-Infected women during pregnancy: self-report versus meconium analysis.

Authors:  Katherine Tassiopoulos; Jennifer S Read; Susan Brogly; Kenneth Rich; Barry Lester; Stephen A Spector; Ram Yogev; George R Seage
Journal:  AIDS Behav       Date:  2010-12

2.  Maternal post-absorptive leucine kinetics during late pregnancy in US women with HIV taking antiretroviral therapy: a cross-sectional pilot study.

Authors:  W Todd Cade; Gautam K Singh; Mark R Holland; Dominic N Reeds; E Turner Overton; Nancy Cibulka; Karen Bahow; Rachel Presti; Andrea Stephens; Alison G Cahill
Journal:  Clin Nutr ESPEN       Date:  2015-08-01

3.  Small for gestational age birth outcomes in pregnant women with perinatally acquired HIV.

Authors:  Jennifer Jao; Keith M Sigel; Katherine T Chen; Gabriela Rodriguez-Caprio; Roberto Posada; Gail Shust; Juan Wisnivesky; Elaine J Abrams; Rhoda S Sperling
Journal:  AIDS       Date:  2012-04-24       Impact factor: 4.177

Review 4.  Role of the placenta in adverse perinatal outcomes among HIV-1 seropositive women.

Authors:  William Ackerman; Jesse J Kwiek
Journal:  J Nippon Med Sch       Date:  2013       Impact factor: 0.920

5.  Growth patterns in the first year of life differ in infants born to perinatally vs. nonperinatally HIV-infected women.

Authors:  Jennifer Jao; Allison Agwu; Grace Mhango; Annie Kim; Kaye Park; Roberto Posada; Elaine J Abrams; Nancy Hutton; Rhoda S Sperling
Journal:  AIDS       Date:  2015-01-02       Impact factor: 4.177

6.  Safety of tenofovir use during pregnancy: early growth outcomes in HIV-exposed uninfected infants.

Authors:  George K Siberry; Paige L Williams; Hermann Mendez; George R Seage; Denise L Jacobson; Rohan Hazra; Kenneth C Rich; Raymond Griner; Katherine Tassiopoulos; Deborah Kacanek; Lynne M Mofenson; Tracie Miller; Linda A DiMeglio; D Heather Watts
Journal:  AIDS       Date:  2012-06-01       Impact factor: 4.177

Review 7.  Impact of HIV-1 infection on the feto-maternal crosstalk and consequences for pregnancy outcome and infant health.

Authors:  Marcus Altfeld; Madeleine J Bunders
Journal:  Semin Immunopathol       Date:  2016-07-08       Impact factor: 9.623

8.  Perinatal Antiretroviral Exposure and Prevented Mother-to-child HIV Infections in the Era of Antiretroviral Prophylaxis in the United States, 1994-2010.

Authors:  Kristen M Little; Allan W Taylor; Craig B Borkowf; Maria C B Mendoza; Margaret A Lampe; Paul J Weidle; Steven R Nesheim
Journal:  Pediatr Infect Dis J       Date:  2017-01       Impact factor: 2.129

Review 9.  Global report on preterm birth and stillbirth (3 of 7): evidence for effectiveness of interventions.

Authors:  Fernando C Barros; Zulfiqar Ahmed Bhutta; Maneesh Batra; Thomas N Hansen; Cesar G Victora; Craig E Rubens
Journal:  BMC Pregnancy Childbirth       Date:  2010-02-23       Impact factor: 3.007

Review 10.  Antiretroviral medications during pregnancy for therapy or prophylaxis.

Authors:  Alice Marie Stek
Journal:  Curr HIV/AIDS Rep       Date:  2009-05       Impact factor: 5.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.